Topic: fatty liver disease
Fractyl presented new data from two trials of its intestine-resurfacing procedure, including demonstrated improvements in Type 2 diabetes.
Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.
Scientists have long known that fatty livers can significantly increase the risk of the organ developing cancer. Now, early research shows why.
For $250 million up front, Akcea is licensing an antisense therapy to Pfizer, to be developed for “certain cardiovascular and metabolic diseases.”
Expectations for NASH are still sky-high—some see billions for any drug that gets it right at peak—but the reality of clinical trials has been murky.
As Genfit hopes for phase 3 successes and filings for its liver disease drug, its CEO and co-founder Jean-François Mouney is stepping aside.
A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.
Targeting fatty lipids known as ceramides reverses insulin resistance and fatty liver, scientists from the University of Utah and Merck found.
NGM presented data showing that its once-monthly nonalcoholic steatohepatitis drug improved insulin sensitivity in people with diabetes.
Bioclinica is launching a new service aimed at reducing the need for liver biopsies in nonalcoholic steatohepatitis trials.